GLP-1May 10, 2026
A daily 25 mg pill of semaglutide produced 13.6% body-weight loss in 307 adults over 64 weeks of treatment, compared with 2.2% on placebo. That is the trial that put a pill version of Wegovy on the market. The injection still wins by a hair, around 14.9% in the largest weight-loss trial of the 2.4 mg weekly dose, but the gap is smaller than most people expect from swapping a needle for a tablet.
The shot has dominated the GLP-1 weight-loss conversation since launch for one practical reason: needles work, and absorbing a peptide drug from a tablet is genuinely hard. The chemistry has now caught up. If your only objection to semaglutide is that you do not want to inject yourself, that objection no longer settles the question.
GLP-1May 10, 2026
In the trial that got Zepbound approved, the average person on the highest 15 mg dose lost 20.9% of their body weight over 72 weeks. The 10 mg dose was 19.5%, and the 5 mg dose was 15.0%. The highest dose wins on paper, but only by 1.4 percentage points over 10 mg, while gastrointestinal side effects keep rising and discontinuation creeps up.
If you're thinking about Zepbound, the more useful question isn't which dose produces the absolute most weight loss in a trial. It's which dose produces the most weight loss YOU can actually stay on for a year or longer. Those answers can differ.
GLP-1May 10, 2026
In the largest trial of Zepbound for weight loss, people on the highest dose lost an average of 20.9% of their body weight over 72 weeks. That's the kind of number that, before tirzepatide arrived, only showed up in bariatric surgery papers.
Zepbound is the obesity-indication brand name for tirzepatide, a once-weekly injection developed by Eli Lilly. It's the same molecule sold as Mounjaro for type 2 diabetes.
Over the past four years, the SURMOUNT trial program has tested it across populations: adults with obesity but no diabetes, adults with obesity plus type 2 diabetes, people who already lost weight through lifestyle changes, Chinese adults, and people with sleep apnea or heart failure. The pattern is consistent. Weight loss is large, dose-dependent, and largely vanishes when the drug is stopped.
Metabolic HealthMay 10, 2026
In the only randomized trial that put tirzepatide directly against semaglutide for weight loss, people on tirzepatide lost an average of 20.2% of their starting weight. People on semaglutide lost 13.7%. The 6.5-percentage-point gap held across nearly every secondary outcome the trial measured.
That difference matters because the choice between these two drugs is rarely about whether they work. Both work. The question is how much extra benefit tirzepatide buys, what it costs in side effects, and whether semaglutide's longer track record on heart outcomes outweighs the smaller weight number.
Colon CancerMay 10, 2026
Colorectal cancer stands as one of the deadliest cancers worldwide, yet it is also one of the most preventable. For women, the story of prevention often begins with a single procedure: the colonoscopy. More than just a diagnostic tool, the evidence from large-scale studies, clinical trials, and decades of clinical practice strongly suggests that the colonoscopy is indispensable for early detection in women.
Cholesterol ManagementMay 10, 2026
After 9 hours at hot room temperature, Repatha (evolocumab) loses about 10% of its PCSK9-inhibiting activity, and after 18 hours that loss climbs to 15%.
That matters because the drug's job is to drop LDL cholesterol by roughly 60%, which translates into about a 15% reduction in the combined risk of cardiovascular death, heart attack, stroke, hospitalization for unstable angina, and coronary revascularization in people with established cardiovascular disease. A medication doing that much heavy lifting shouldn't be quietly losing potency on a kitchen counter.
So how long can a Repatha pen actually sit out of the fridge before you should worry? The honest answer depends on three variables: ambient temperature, time, and whether you put a cold pack near it.
CancerMay 10, 2026
Cologuard catches more than 9 out of 10 colorectal cancers but only about 4 out of 10 advanced precancerous lesions. That asymmetry is the most important thing to understand about how the test works, and it explains both why Cologuard exists and why colonoscopy hasn't been replaced.
If you're choosing between screening options, accuracy isn't a single number. It's a trade-off: how often the test correctly flags cancer, how often it catches polyps before they turn into cancer, and how often it cries wolf. Cologuard handles those three things very differently from each other, and the numbers have shifted with the next-generation version.
Cholesterol ManagementMay 10, 2026
In a trial of 27,564 people with established heart disease, Repatha pushed average LDL cholesterol from 92 mg/dL down to 30 mg/dL. That is roughly a 60% drop, achieved on top of statins, sustained for years. The same trial also showed an 18% drop in major cardiovascular events: heart attacks, strokes, and the procedures used to fix them.
Most articles you find about Repatha (evolocumab) are either drug-company brochures or anonymous internet comment threads. The actual reviews you should care about live inside randomized trials and real-world registries that have now followed hundreds of thousands of patient-years on this medication. The picture they paint is consistent: a powerful LDL-lowering injection with a side-effect profile that surprises people for how light it is, paired with hard outcome data that explain why cardiologists keep adding it to high-risk patients despite the price tag.
Cardiovascular HealthMay 10, 2026
Heart disease risk is not just about diet, exercise, or cholesterol numbers. Genetics play a major role, often long before symptoms appear. Understanding inherited risk helps us detect disease earlier, intervene more aggressively, and personalize prevention and treatment.
CancerMay 10, 2026
Megestrol acetate can make you hungrier and help you gain a little weight. But across large systematic reviews, it has never been shown to help people live longer. That tension sits at the heart of every decision to prescribe this drug: it treats a symptom (wasting, lost appetite) while carrying real risks to your endocrine system, your blood vessels, and your metabolism. Whether that tradeoff makes sense depends entirely on what problem you're trying to solve.
Megestrol acetate is a synthetic progestin, meaning it mimics progesterone. It was originally developed as a hormonal cancer treatment and is still used that way. But its most common role today is as an appetite stimulant for people dealing with the severe weight loss and appetite collapse that come with cancer, AIDS, and other serious illnesses.
Cholesterol ManagementMay 10, 2026
In a real-world registry of patients on PCSK9 inhibitors, 71.1% of all reported side effects resolved during follow-up. That's not a marketing claim. It's the headline finding from a Dutch pharmacovigilance dataset that tracked what actually happened to people who flagged a problem with the drug.
If you just started Repatha (or are about to), this is the question that matters: will the sting at the injection site, the muscle ache, the flu-like feeling stick around, or pass? The answer depends on which side effect, but the data is reassuring across most of them. Long-term trials following patients for up to 8.4 years on Repatha show that adverse event rates don't climb over time, and in some cases actually decline.
CancerMay 10, 2026
In the trial that won Cologuard FDA approval, the test found 92.3% of colorectal cancers and 42.4% of advanced precancerous polyps in nearly 10,000 average-risk adults. That single split tells you almost everything about how to think about it.
The test is excellent at catching cancer that already exists. It is much less reliable at finding the polyps that might quietly turn into cancer over the next decade.
That distinction matters because most colorectal cancer screening is really about removing precursors before they become anything serious. So "is Cologuard accurate?" depends on which question you are actually asking the test.
Prostate CancerMay 10, 2026
When people think of prostate cancer, they usually associate it with men. This is because the prostate is a small gland found in individuals assigned male at birth. Its primary role is to produce seminal fluid that nourishes and transports sperm. However, the question of whether women can get prostate cancer is still more complex than it may appear.
Lab TestingMay 10, 2026
About a third of patients who get treated for syphilis still have a reactive RPR test a year after their last antibiotic dose. In a study of 1,327 HIV-negative patients followed for a year, 34.4% remained in what doctors call a "serofast" state, with persistently positive titers despite finishing the standard penicillin regimen. The bacteria are usually gone. The antibody fingerprint isn't.
That mismatch is the heart of why RPR titer interpretation feels so confusing. The result reads like a fraction (1:8, 1:32, 1:128), the lab calls it "reactive" or "nonreactive," and the practical meaning depends on numbers most patients never see explained: where the titer is, where it was, and how much it has moved.
Weight ManagementMay 10, 2026
If you are starting Repatha and you have heard horror stories about cholesterol medications and weight gain, the trial evidence is reassuring. Across 27,564 patients followed for a median of 2.2 years, Repatha (evolocumab) produced no excess in new-onset diabetes, no shift in glycemic markers, and no overall adverse-event difference compared to placebo. Weight gain is not among the adverse events the trial flagged; the only excess was mild injection-site reactions at 2.1% vs 1.6%.
This matters because the question of "does this cholesterol drug make me gain weight" gets asked about almost every lipid-lowering medication, even though the underlying mechanisms differ completely. Repatha sits in a different drug class than the medications that built that reputation, and its safety profile in trials reflects that difference.
Colon CancerMay 10, 2026
Most people searching for visual clues in the toilet bowl don't realize that colon cancer changes stool differently depending on where the tumor sits. Left-sided tumors tend to cause visible blood and thinner stools. Right-sided tumors lean toward chronic diarrhea and looser consistency. And some cancers produce changes you can't see at all, detectable only through lab testing.
That distinction matters because it means there is no single "cancer poop" to watch for. Stool appearance alone cannot rule in or rule out colon cancer. But the clinical patterns are specific enough to know when something deserves a doctor's attention.
Prostate CancerMay 10, 2026
Prostate cancer is the most common cancer in men and the second leading cause of cancer death worldwide. Nearly one in six men will face a diagnosis during their lifetime, and in the United States alone, hundreds of thousands of men are diagnosed each year. The disease often develops silently, with no symptoms until it has advanced, which makes screening especially important.
As Prostate Cancer Awareness Month nears its end, it's important to highlight the tests that make the greatest impact on early detection. While most doctors still rely on total PSA, clinical research shows that free PSA delivers stronger predictive value by distinguishing cancer from benign conditions and reducing unnecessary biopsies.
MetforminMay 10, 2026
No clinical trial has ever compared morning versus evening metformin dosing for weight loss. Not one. The question sounds reasonable, but the research simply hasn't found that clock time matters. What does matter: your total daily dose, whether you can tolerate it, and how long you stick with it.
Metformin produces real but modest weight loss in people with overweight or obesity, roughly 0.5 BMI units, or about 2 to 3 percent of body weight, over three months or more at doses ranging from 500 to 2,550 mg per day. That's meaningful, but it's not dramatic, and trying to optimize the hour you swallow the pill won't change that math.
Cardiovascular HealthMay 10, 2026
Berberine, a golden-yellow alkaloid found in plants such as Berberis vulgaris and Coptis chinensis, has a long history of use in traditional healing systems. In recent years, it has become the focus of modern biomedical research because of its wide-ranging effects on blood sugar, cholesterol, and inflammation. While its popularity as a dietary supplement is steadily increasing, many patients still ask us whether it could be harmful to the kidneys.
The kidneys are essential for filtering blood, balancing electrolytes, and maintaining overall metabolic stability. Because berberine is metabolically active, it is reasonable to wonder how it might influence kidney health over time. The available research, however, paints a picture that is far more promising than dangerous.
Digestive DisordersMay 10, 2026
About 60% of adults with lymphocytic colitis experience a single episode that resolves on its own. That's a striking number for a condition that can cause weeks or months of relentless watery diarrhea, urgency, and real disruption to daily life. But here's the catch: because the colon looks perfectly normal during a standard colonoscopy, many people cycle through appointments and tests before anyone thinks to take a biopsy. Without that biopsy, lymphocytic colitis is invisible.
Lymphocytic colitis (LC) is a form of microscopic colitis, meaning the inflammation only shows up under a microscope. It typically strikes middle-aged to older adults, with a median age around 59 to 67 years, and is more common in women. The hallmark is chronic, watery, non-bloody diarrhea, often accompanied by abdominal pain, weight loss, and sometimes fecal incontinence. It can significantly affect quality of life even though it carries a largely benign prognosis.
